

Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings

2015 update



World Health
Organization

HMTB

Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings

2015 update



**World Health
Organization**

HMTB

This is an update to the 2011 WHO Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings

http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf?ua=1

WHO Library Cataloguing-in-Publication Data

Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update.

1. Tuberculosis - prevention and control. 2. Tuberculosis - diagnosis. 3. HIV Infections - complications. 4. Isoniazid - therapeutic use. 5. Predictive Value of Tests. 6. Developing Countries. 7. Guideline. I. World Health Organization.

ISBN 978 92 4 150887 2 (NLM classification: WF 220)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by North Creative, Geneva, Switzerland

WHO/HTM/TB/2015.15

WHO/HIV/2015.13

Contents

Acknowledgements	2
Declaration and management of conflict of interest	4
Executive summary	6
1. Background and process	7
1.1 Background	7
1.2 Scope of the update to the recommendation	7
1.3 Target audience for the update	7
1.4 Process of development of the guidelines	7
2. Recommendation	9
2.1 Summary of the evidence	9
2.1.1 Incidence of active TB and mortality	9
2.1.2 Adverse events	9
2.1.3 Adherence	9
2.1.4 Effect of TST	10
2.1.5 Effect of concomitant use of IPT with ART	10
2.1.6 Drug resistance	10
2.1.7 Cost-effectiveness of 36 months of IPT	10
2.1.8 Conclusions on the evidence	10
2.2 Balance of benefits and harms	10
2.3 Values and preferences of clients and health-care providers	11
2.4 Resource considerations	11
2.5 Conclusion	11
References	12
Annex 1: Evidence-to-decision framework	13

Acknowledgements

Overall coordination and writing of the guidelines

Alberto Matteelli with input from Haileyesus Getahun.

WHO Steering Group

Dennis Falzon (Global TB Programme, WHO), Nathan Ford (HIV/AIDS Department, WHO), Haileyesus Getahun (Global TB Programme, WHO), Chris Gilpin (Global TB Programme, WHO), Christian Lienhardt (Global TB Programme, WHO), Knut Lönnroth (Global TB Programme, WHO), Alberto Matteelli (Global TB Programme, WHO), Lisa Nelson (HIV/AIDS Department, WHO), Andreas Reis (Knowledge, Ethics and Research Department, WHO), Mukund Uplekar (Global TB Programme, WHO).

Co-chairs of the WHO Guidelines Development Group

Holger Schünemann (McMaster University Health Sciences Centre, Canada), Jay Varma (US Centers for Disease Control and Prevention, United States of America, [USA]).

GRADE methodologist for the WHO Guidelines Development Group

Holger Schünemann (McMaster University Health Sciences Centre, Canada).

Members of the WHO Guidelines Development Group

Ibrahim Abubakar (National Centre for Infectious Disease Surveillance and Control, University College London and Public Health England, United Kingdom of Great Britain and Northern Ireland), Draurio Barreira (National TB Programme, Ministry of Health, Brazil), Susana Marta Borroto Gutierrez (Pedro Kourí Institute of Tropical Medicine, Cuba), Judith Bruchfeld (Karolinska Institute and Karolinska University Hospital, Sweden), Erlina Burhan (Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Indonesia), Solange Cavalcante (Rio de Janeiro Municipal Health Secretariat FIOCRUZ, Brazil), Rolando Cedillos (Servicio de Infectología y Programade Atención Integral en ITS/VIH/SIDA, El Salvador), Richard Chaisson (Center for TB Research, Johns Hopkins University, USA), Cynthia Bin-Eng Chee (Tan Tock Seng Hospital, Singapore), Lucy Chesire (TB Advocacy Consortium, Kenya), Elizabeth Corbett (London School of Hygiene & Tropical Medicine, United Kingdom), Justin Denholm (Royal Melbourne Hospital, Australia), Gerard de Vries (KNCV TB Foundation, the Netherlands), Margaret Gale-Rowe (Public Health Agency of Canada, Canada), Un-Yeong Go (Department of HIV/AIDS and TB Control Korea, Korea Centers for Disease Control and Prevention, Republic of Korea), Alison Grant (London School of Hygiene & Tropical Medicine, United Kingdom), Robert Horsburgh (Department of Epidemiology, Boston University School of Public Health, USA), Asker Ismayilov (Main Medical Department, Ministry of Justice, Azerbaijan), Philippe LoBue (Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, USA), Guy Marks (Woolcock Institute of Medical Research, University of Sydney, Australia), Richard Menzies (Respiratory Division, McGill University, and Montreal Chest Institute, Canada), Giovanni Battista Migliori (WHO Collaborating Centre for TB and Lung Diseases Fondazione Salvatore Maugeri, Italy), Davide Mosca (Migration Health Department, International Organization of Migration, Switzerland), Ya Diul Mukadi (Infectious Disease Division, Bureau for Global Health, US Agency for International Development, USA), Alwyn Mwinga (Zambart Project, Zambia), Lisa Rotz (Centers for Disease Control and Prevention, USA), Holger Schünemann (Clinical Epidemiology & Biostatistics, McMaster University, Canada), Surender Kumar Sharma (Department of Medicine, All India Institute of Medical Sciences, India), Timothy Sterling (Vanderbilt University School of Medicine, USA), Tamara Tayeb (Ministry of Health, Saudi Arabia), Marieke van der Werf (European Centre for Disease Prevention and Control, Sweden), Wim Vandewelde (European AIDS Treatment Group, Belgium), Jay Varma (US Centers for Diseases Control and Prevention, USA), Natalia Vezhnina (HIV/TB and Penal System Projects, Russian Federation), Constantia Voniatis (Clinical Laboratories, Ministry of Health, Cyprus), Robert John Wilkinson (Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa), Takashi Yoshiyama (Division of Respiratory Medicine, Japan Anti-Tuberculosis Association, Japan), Jean Pierre Zellweger (Tuberculosis Competence Centre, Switzerland).

WHO consultant for systematic review

Saskia den Boon (Independent consultant, Switzerland).

Peer Review Group

Helen Ayles (Zambart Project, Zambia), Constance Benson (University of California, USA), Amy Bloom (US Agency for International Development, USA), Graham Bothamley (Tuberculosis Network, European Study Group Clinical trials, United Kingdom), Gavin Churchyard (The Aurum Institute, South Africa), Daniela Maria Cirillo (San Raffaele del Monte Tabor Foundation, San Raffaele Scientific Institute, Italy), Frank Cobelens (KNCV Tuberculosis Foundation, the Netherlands), Robert Colebunders (Institute of Tropical Medicine, Belgium), Charles Daley (University of Colorado, USA), Riitta Dlodlo (International Union against TB and Lung Diseases, Zimbabwe), Raquel Duarte (General Directorate of Health, Portugal), Connie Erkens (KNCV Tuberculosis Foundation, the Netherlands), Brian Farrugia (Geriatric Medicine and Chest Clinic, Malta), Michel Gasana (National TB Programme, Rwanda), Stephen Graham (Centre for International Child Health, Australia), Mark Harrington (Treatment Action Group, USA), Antony Harris (International Union against TB and Lung Diseases, France), Barbara Hauer (Robert Koch Institute, Germany), Diane Havlir (University of California, USA), Einar Heldal (International Union against TB and Lung Diseases, Norway), Rein Houben (Tuberculosis Modelling and Analysis Consortium, United Kingdom), Mohamed Akramul Islam (BRAC Health Programme, Bangladesh), Jerker Jonsson (Swedish Institute for Infectious Disease Control, Sweden), Michael Kimerling (Bill & Melinda Gates Foundation, USA), Christopher Lange (Clinical Infectious Diseases, Medical Clinic Research Center, Germany), Wang Lixia (National Centre for TB Control and Prevention, China), Gary Maartens (University of Cape Town, South Africa), Joan O'Donnell (National TB Programme, National Disease Surveillance Unit, Ireland), Anshu Prakash (Ministry of Health and Family Welfare, India), Ejaz Qadeer (National TB Control Programme, Federal Ministry of Health, Pakistan), Lidija Ristic (Committee for TB, Ministry of Health, Serbia), Laura Sanchez-Cambronero (Ministry of Health, Social Services and Equality, Spain), Andreas Sandgren (European Centre for Disease Prevention and Control, Sweden), Martina Sester (Saarland University, Germany), Joseph Kimagut Sitienei (Ministry of Public Health, Kenya), Alena Skrahina (Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Belarus), Ivan Solovic (National Institute for TB, Lung Diseases and Thoracic Surgery, Slovakia), Elena Suciliene (Children's Hospital, affiliate of Vilnius University Hospital Santariskiu Klinikos, Lithuania), Soumya Swaminathan (National Institute for Research in Tuberculosis, India), Maarten van Cleeff (KNCV Tuberculosis Foundation, the Netherlands), Francis Varaine (Médecins Sans Frontières, France), Martina Vasakova (Respiratory Diseases and Pulmonology Department at Prague Thomayer Hospital, Czech Republic), Irina Vasilyeva (Ministry of Health, Russian Federation), Mercedes Vinuesa Sebastián (Ministry of Health, Spain), Dalene von Delft (TB PROOF, South Africa), Brita Askeland Winje (Norwegian Institute of Public Health, Norway), Dominik Zenner (Public Health England, United Kingdom).

WHO headquarters and regional offices

Mohamed Abdel Aziz (WHO/EMRO), Annabel Baddeley (WHO/HQ), Masoud Dara (WHO/EURO), Malgorzata Grzemska (WHO/HQ), Ernesto Jaramillo (WHO/HQ), Nobuyuki Nishikiori (WHO/WPRO), Diana Weil (WHO/HQ), Karin Weyer (WHO/HQ).

Acknowledgement of financial support

The development of these guidelines was supported financially by the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID).

Next update of these guidelines: The next update will be done in conjunction with the revision of the 2011 WHO "Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings".

Declaration and management of conflict of interest

All the contributors completed a WHO Declaration of Interest form. All stated declarations of interest were evaluated by three members of the Steering Group (the Legal Department of WHO was consulted when necessary) for the existence of possible financial conflicts of interest which warrant exclusion from membership of the Guidelines Development or Peer Review Groups or from the discussions as part of the guidelines development process. Intellectual conflict of interest was not considered grounds for exclusion from membership of the Guidelines Development Group as broader expertise on Latent TB Infection (LTBI) was the main criteria for selection and representation on the group; the group itself was felt to be large enough to overcome any potential intellectual conflict of interest. During the guidelines development process and the Guideline Development Group meeting, any emergence of intellectual conflict of interest was monitored by the Chairs and the Coordinator of the Secretariat, and any perceived intellectual conflict of interest was discussed with members of the Guidelines Development Group.

The following interests were declared:

WHO Guidelines Development Group:

Ibrahim Abubakar declared that his employer received grants from the National Institutes of Health (£2.7 million for the PREDICT study: Prognostic Evaluation of Interferon Gamma Release Assays (IGRAs) and Skin test in a cohort of 10 000 contacts and migrants) and the UK Department of Health (£900 000 for a randomized controlled trial to assess isoniazid-rifapentine compared to isoniazid-rifampicin on LTBI treatment completion and £490 000 for the Academic, Clinical & Enterprise (ACE) study, and detection of latent TB in emergency departments). He is currently the chair of the UK National Institute for Health and Care Excellence (NICE) guideline development group developing guidelines on TB which includes active and latent TB treatment. NICE pays his employer (University College London) for his time at about £500 a day. He was a member of the European Centre for Disease Prevention and Control (ECDC) guideline development group on IGRAs published in 2011, for which he did not receive any remuneration. He has written extensively on this subject including a recent commentary in The Lancet on LTBI in the UK.

Cynthia Bin-Eng Chee declared that she has attended meetings pertaining to IGRAs sponsored by Qiagen (1st meeting of Asia TB Experts Community, Chiba, Japan 13 May 2012 and the 2nd Meeting of Asia TB Experts Community, Bangkok, Thailand, July 2013) and University of California, San Diego (3rd Global IGRA Symposium, Waikoloa, Hawaii, January 2012) with an estimated overall value of US\$ 4500 for travel and accommodation.

Richard Chaisson declared that he received remuneration for consulting on TB drug development from Vertex of US\$ 2000 in 2012 one time only and received research grants from the National Institutes of Health, the Centers for Disease Control and Prevention (CDC) and the Gates Foundation of more than US\$ 15 million which is ongoing.

Liz Corbett declared that her employer received research grants concerning the public health impact of combined TB prevention from Wellcome Trust grants

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27404

